Tűz Boglárka, Correia Isabel, Martinho Paulo N
Centro de Química Estrutural, Institute of Molecular Sciences, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal.
Centro de Química Estrutural, Institute of Molecular Sciences and Department of Chemical Engineering, Instituto Superior Técnico, Universidade de Lisboa, Avenida Rovisco Pais, 1049-001 Lisboa, Portugal.
J Inorg Biochem. 2025 Mar;264:112813. doi: 10.1016/j.jinorgbio.2024.112813. Epub 2024 Dec 15.
Due to their diverse chemical properties and high ability to interact with biological molecules and cellular processes, transition metal-based compounds have emerged as promising candidates for cancer therapy. Iron complexes are among them, however, there is a gap in the comprehensive analysis of heterometallic iron complexes in the anticancer field. This review aims to fill this gap by summarizing recent progress in the study of Fe(II) and Fe(III) heterobimetallic complexes for anticancer applications and to gather important insights and future perspectives, with special emphasis on their theranostic capabilities. Works published between 2014 and 2024 were considered in this critical survey, that covers a range of complex types, including ferrocene in bimetallic complexes with Pt, Pd, Au, Ag, Ru, Rh, Ir, Cu, Re, Sn and Co; organometallic Fe-complexes with Ru and Ag; photoactive metal complexes with Pt and Co; and magnetic resonance imaging contrast agents with Gd and Mn. Studies conducted to determine the modes of action are highlighted and suggest the involvement of the metal species in reactive oxygen species generation within cells, the impact on apoptosis and cell cycle arrest, and many others. By pursuing interdisciplinary research, innovative theranostic platforms with enhanced efficacy, specificity, and clinical relevance can be developed for cancer management.
由于其多样的化学性质以及与生物分子和细胞过程相互作用的高能力，过渡金属基化合物已成为癌症治疗的有前景的候选物。铁配合物就在其中，然而，在抗癌领域对异金属铁配合物的综合分析方面存在差距。本综述旨在通过总结用于抗癌应用的Fe(II)和Fe(III)异双金属配合物研究的最新进展来填补这一差距，并收集重要的见解和未来展望，特别强调它们的诊疗能力。在本次关键调查中考虑了2014年至2024年间发表的作品，该调查涵盖了一系列复杂类型，包括与Pt、Pd、Au、Ag、Ru、Rh、Ir、Cu、Re、Sn和Co形成的双金属配合物中的二茂铁；与Ru和Ag形成的有机金属铁配合物；与Pt和Co形成的光活性金属配合物；以及与Gd和Mn形成的磁共振成像造影剂。突出了为确定作用模式而进行的研究，并表明金属物种参与细胞内活性氧的产生、对细胞凋亡和细胞周期停滞的影响等等。通过开展跨学科研究，可以开发出具有更高疗效、特异性和临床相关性的创新诊疗平台用于癌症管理。
